Literature DB >> 4743096

Biopharmaceutics of drugs administered in lipid-containing dosage forms. I. GI absorption of griseofulvin from an oil-in-water emulsion in the rat.

P J Carrigan, T R Bates.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4743096     DOI: 10.1002/jps.2600620918

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  8 in total

1.  Modification of intestinal absorption of drugs by lipoidal adjuvants.

Authors:  S Muranishi
Journal:  Pharm Res       Date:  1985-05       Impact factor: 4.200

2.  Enhanced intestinal absorption of cyclosporine in rats through the reduction of emulsion droplet size.

Authors:  B D Tarr; S H Yalkowsky
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

3.  Dissolution rate and bioavailability of griseofulvin from a ground mixture with microcrystalline cellulose.

Authors:  K Yamamoto; M Nakano; T Arita; Y Nakai
Journal:  J Pharmacokinet Biopharm       Date:  1974-12

4.  Influence of bile salts and lipids on intestinal absorption of griseofulvin in man.

Authors:  R Palma; N Vidon; G Houin; A Pfeiffer; M Rongier; J Barre; J J Bernier
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 5.  The Precipitation Behavior of Poorly Water-Soluble Drugs with an Emphasis on the Digestion of Lipid Based Formulations.

Authors:  Jamal Khan; Thomas Rades; Ben Boyd
Journal:  Pharm Res       Date:  2015-11-23       Impact factor: 4.200

6.  Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans.

Authors:  H Cheng; J D Rogers; J L Demetriades; S D Holland; J R Seibold; E Depuy
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

7.  Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.

Authors:  Anne Larsen; René Holm; Mette Lund Pedersen; Anette Müllertz
Journal:  Pharm Res       Date:  2008-07-01       Impact factor: 4.200

8.  New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.

Authors:  Niklas J Koehl; René Holm; Martin Kuentz; Brendan T Griffin
Journal:  Pharm Res       Date:  2019-02-22       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.